Serena G. Liao

Efficacy and Safety of Vemircopan in Generalized Myasthenia Gravis

Francesco Saccà, Gino Gialdini, James F. Howard, Tuan Hoang Vu et autres

Importance: Inhibition of terminal complement component 5 has proven effective in acetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis (gMG) but requires intravenous or daily subcutaneous administration and is associated with an increased meningococcal infection risk. Targeting the complement alternative pathway (AP) may …

it, us, de, rs, ca, tw, es (code pays fourni par la source)

Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study

Andreas Meisel, James F. Howard, Tuan Vu, Hani A. Kushlaf et autres

INTRODUCTION/AIMS: The CHAMPION MG study demonstrated that ravulizumab significantly improved Myasthenia Gravis-Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) total scores versus placebo in adults with acetylcholine receptor antibody-positive generalized myasthenia gravis (AChR+ gMG). This post hoc analysis aimed to …

us (code pays fourni par la source)

Time to response with ravulizumab, a long‐acting terminal complement inhibitor, in adults with anti‐acetylcholine receptor antibody‐positive generalized myasthenia gravis

Masahisa Katsuno, Shahram Attarian, Michael G Benatar, Kathleen N. Beasley et autres

BACKGROUND AND PURPOSE: The efficacy and safety of ravulizumab, a terminal complement C5 inhibitor, in adults with anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG) were demonstrated in the CHAMPION MG study (NCT03920293). This analysis aimed to characterize the latency to …

us (code pays fourni par la source)

Time to response with ravulizumab, a long‐acting terminal complement inhibitor, in adults with anti‐acetylcholine receptor antibody‐positive generalized myasthenia gravis

Ali Aamer Habib, Michael G Benatar, Tuan Vu, Andreas Meisel et autres

BACKGROUND AND PURPOSE: The efficacy and safety of ravulizumab, a terminal complement C5 inhibitor, in adults with anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG) were demonstrated in the CHAMPION MG study (NCT03920293). This analysis aimed to characterize the latency to …

us, de, fr, jp (code pays fourni par la source)

Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study

John Frederick Brandsema, Matthew R. Ginsberg, Hideki Hoshino, Masakazu Mimaki et autres

BACKGROUND: This study evaluated the efficacy and safety of eculizumab, a terminal complement C5 inhibitor, in juvenile generalized myasthenia gravis (gMG). METHODS: Adolescents aged 12 to 17 years with refractory anti-acetylcholine receptor (AChR) antibody-positive gMG received eculizumab (weekly induction [one to two …

us, jp, ch (code pays fourni par la source)

Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study

James F. Howard, Tuan Vu, Renato Mantegazza, Hani A. Kushlaf et autres

INTRODUCTION/AIMS: The CHAMPION MG study demonstrated that ravulizumab significantly improved Myasthenia Gravis-Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) total scores versus placebo in adults with acetylcholine receptor antibody-positive generalized myasthenia gravis (AChR+ gMG). This post hoc analysis aimed to …

us, it, jp, de (code pays fourni par la source)

Ravulizumab for the Treatment of Generalized Myasthenia Gravis: Timing of Response (P1-5.004)

Habib Moussa Ali, Michael G Benatar, Tuan Hoang Vu, Andreas Meisel et autres

To assess the timing of first response to ravulizumab in patients with generalized myasthenia gravis (gMG) in the CHAMPION MG study.

us, de, fr, jp, br, ch (code pays fourni par la source)

A Phase 3, Open-Label, Multicenter Study To Evaluate Eculizumab In Adolescents With Refractory Generalized Myasthenia Gravis (S5.009)

John Frederick Brandsema, Matthew R. Ginsberg, Hideki Hoshino, Masakazu Mimaki et autres

Objective: To evaluate eculizumab for the treatment of adolescents with refractory anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG). Background: Patients with AChR Ab+ gMG have uncontrolled complement activation leading to neuromuscular junction destruction and impaired neuromuscular transmission, resulting in debilitating …

us, jp (code pays fourni par la source)

Achievement of Improved Post-Intervention Status in Patients with Generalized Myasthenia Gravis Treated with Ravulizumab during the CHAMPION MG Study (S5.008)

Srikanth Muppidi, Pushpa Narayanaswami, Andreas Meisel, Tuan Vu et autres

Objective: To determine whether ravulizumab treatment enables patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis (AChR Ab+ gMG) to achieve the Myasthenia Gravis Foundation of America Post-Intervention Status (MGFA-PIS) of “improved”, with or without achieving minimal manifestation status (MMS). Background: The 26-week, …

us, il, de, jp, it, br, ch (code pays fourni par la source)

Supplementary Figure 3 from Targeted DNA Methylation Screen in the Mouse Mammary Genome Reveals a Parity-Induced Hypermethylation of Igf1r That Persists Long after Parturition

Tiffany A. Katz, Serena G. Liao, Vincent J. Palmieri, Robert K. Dearth et autres

Supplemental Figure S3. Mapping efficiency was above 50 for all samples in both time points. One sample was an outlier in the early time point (P12) and one at the late time point (NP4) and were removed from further analysis. Both Pearson …

Supplementary Table 1 from Targeted DNA Methylation Screen in the Mouse Mammary Genome Reveals a Parity-Induced Hypermethylation of Igf1r That Persists Long after Parturition

Tiffany A. Katz, Serena G. Liao, Vincent J. Palmieri, Robert K. Dearth et autres

Primers used for quantitative PCR and bisulfite sequencing.

Supplementary Data 1 from Targeted DNA Methylation Screen in the Mouse Mammary Genome Reveals a Parity-Induced Hypermethylation of Igf1r That Persists Long after Parturition

Tiffany A. Katz, Serena G. Liao, Vincent J. Palmieri, Robert K. Dearth et autres

Supplemental Data 1. This spreadsheet contains the results of the differential methylation analysis, the meta-analysis and the pathway analysis. In the meta-analysis sheets, the first 3 columns represent the chromosomal locations, followed by the significance level (stat, p-value, and FDR). Weight.1 and …